Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Positive late-breaking news on a new pathway – Factor XIa inhibition – for antithrombotic treatment for stroke risk reduction
Secondary prevention trial in patients (>12,000 pts) after non-cardioembolic ischemic stroke or high-risk TIA
OCEANIC-STROKE demonstrates superiority of asundexian vs. Placebo (in both study arms in combo with antiplatelet therapy), showing significant reduction in ischemic stroke risk, without increasing bleeding risk
OCEANIC-STROKE is the first successfully completed Phase III study of a Factor XIa inhibitor (50 mg p.o. once daily)
Adding an antithrombotic agent (here: asundexian) to best medical treatment (here: antiplatelet treatment) with significant reduction in ischemic risk and – at the same time – without (!) increasing overall bleeding risk is highly remarkable!
Uncoupling thrombosis- and haemostasis risk”
Read the full article here.
Stay updated with Hemostasis Today.
-
Jul 9, 2026, 06:03Barbara Adams Krolak: ISTH Launches Global Women’s Health Hub
-
Jul 9, 2026, 05:49Abdul Mannan: A Low Platelet Count is not Always a Bone Marrow Problem
-
Jul 9, 2026, 05:41Julieta Rosales: Management of Tandem Strokes – To Stent or Not to Stent?
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation
-
Jul 8, 2026, 21:22What Hundreds of Stroke Stories Have Taught Diana Kerr About Recovery and Resilience – Stroke Foundation
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care